Information  X 
Enter a valid email address

Pfizer Inc (0Q1N)

  Print      Mail a friend

Wednesday 21 May, 2014

Pfizer Inc

Replacement - Form 8 (OPD) (Pfizer)

RNS Number : 6938H
Pfizer Inc
21 May 2014
 


FORM 8 (OPD)

 

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

AMENDMENT - CHANGES TO SECTION 3.3 AND SUPPLEMENTAL FORM

 

1.         KEY INFORMATION

 

(a) Identity of the party to the offer making the disclosure:

Pfizer Inc. ("Pfizer")

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

    

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

    

Pfizer Inc.

(d) Is the party to the offer making the disclosure the offeror or the offeree?

Offeror

(e) Date position held:

9 May 2014

(f)  Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes, AstraZeneca PLC

 

2.         POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Shares of Common Stock (excluding treasury shares)

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil


Nil


(2) Derivatives (other than options):

Nil


Nil


(3) Options and agreements to purchase/sell:

Nil


Nil


 

     TOTAL:

Nil


Nil


 

 

(b)        Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

None.

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

(c)        Irrevocable commitments and letters of intent

 

Details of any irrevocable commitments or letters of intent procured by the party to the offer making the disclosure or any person acting in concert with it (see Note 3 on Rule 2.11 of the Code):

 

None.

 

 

3.         POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe of any person acting in concert with the party to the offer making the disclosure:

 

See below.

 

 

3.1        Pfizer Directors

 

Name

Number of Shares of Common Stock held[1]

Percentage of total issued common stock (excluding treasury shares)

Dennis A. Ausiello

2,362

0.00%

W. Don Cornwell

1,759

0.00%

Constance J. Horner

18,334

0.00%

James M. Kilts

2,259

0.00%

George A. Lorch

24,126

0.00%

Ian C. Read

321,171[2]

0.01%

Suzanne M. Nora Johnson

12,200

0.00%

Stephen W. Sanger

1,085

0.00%

Marc Tessier-Lavigne

104

0.00%

 

 

3.2        Directors' Stock Awards and Options[3]

 

Ian C. Read holds the following stock units/awards:

 

Type of Award

Number held

Restricted Stock Units [4]

377,622

Performance Share Awards [5]

363,099

Deferred [6] Restricted Stock Units

545,027

Deferred Performance Share Awards 

191,130

Pfizer stock units held in the Nonfunded Deferred Compensation and Supplemental Savings Plan [7]

170,011

Total Shareholder Return Units [8]

5,372,015

Stock Options[9]

275,000

 

The directors of Pfizer listed below hold the following stock awards:

 

Name

Number of Director Units[10] held

Dennis A. Ausiello

26,291

W. Don Cornwell

98,929

Frances D. Fergusson

35,451

Helen Hobbs

29,038

Constance J. Horner

135,183

James M. Kilts

94,921

George A. Lorch

97,003[11]

Shantanu Narayen

12,339

Suzanne M. Nora Johnson

42,798

Stephen W. Sanger

77,262

Marc Tessier-Lavigne

23,671

 

 

3.3        Advisers to Pfizer[12]

 

Bank of America Merrill Lynch (Bank of America N.A. and U.S. Trust Co of Delaware)

 

Class of relevant security:

 

Shares of Common Stock

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

1,299,317

0.02%

Nil


(2) Derivatives (other than options):

Nil


Nil


(3) Options and agreements to purchase/sell:

Nil


Nil


 

     TOTAL:

1,299,317

0.02%

Nil


 

J.P. Morgan (J.P. Morgan Securities LLC and J.P. Morgan Trust Company of Delaware)

 

 

Class of relevant security:

 

Shares of Common Stock 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

12,910,482

0.20%

7,528,992

0.12%

(2) Derivatives (other than options):

3,432,511

0.05%

1,336,116

0.02%

(3) Options and agreements to purchase/sell:

1,186,414

0.02%

803,200

0.01%

 

     TOTAL:

17,529,407

0.27%

9,668,308

0.15%

 

 

4.         OTHER INFORMATION

 

(a)        Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

 

None[13]

 

 

(b)        Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i)  the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

 

None

 

 

(c)        Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

Yes

Supplemental Form 8 (SBL)

No

 

 

Date of disclosure:

12 May 2014

Contact name:

Chris Dickinson

Geoff Iles

Telephone number:

+44 (0) 207 134 7302

+44 (0) 207 995 1930

 

 

 


SUPPLEMENTAL FORM 8 (OPEN POSITIONS)

 

DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.[14]

Note 5(i) on Rule 8 of the Takeover Code (the "Code")

 

 

1.         KEY INFORMATION

 

Identity of person whose open positions are being disclosed:

J.P. Morgan Securities LLC

Name of offeror/offeree in relation to whose relevant securities the disclosure relates:

Pfizer Inc.

 

2.         OPTIONS AND DERIVATIVES

 

Class of relevant security

Product description

Written or purchased

Number of securities to which option or derivative relates

Exercise price per unit

(USD)

Type

 

Expiry date

Shares of Common Stock

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Down & In Put Option

Accumulator

Maturity Observation Note

Range Accrual Note

Range Accrual Note

Range Accrual Note

Range Accrual Note

Maturity Observation Note

Maturity Observation Note

 

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

 

Written

Written

Written

Written

Purchased

 

Written

 100

 100

 100

 200

 200

 300

 600

 600

 600

 700

 800

 800

 900

 1,000

 1,000

 1,600

 1,700

 1,900

 2,100

 2,300

 2,700

 3,300

 3,800

 3,900

 4,700

 7,000

 8,300

 12,700

 13,200

 24,100

 25,700

 27,600

 28,700

 52,600

 57,100

 64,741

 66,400

 81,481

 111,800

 269,500

 100

 100

 1,500

 2,200

 2,300

 2,800

 4,400

 4,700

 8,400

 14,300

 19,000

 20,000

 21,800

 25,000

 25,900

 43,900

 63,800

 71,600

 82,300

 88,900

 100

 100

 200

 200

 200

 200

 300

 400

 400

 500

 800

 800

 1,500

 1,900

 2,500

 4,100

 4,600

 5,100

 5,900

 6,700

 6,800

 7,400

 8,200

 16,700

 18,000

 23,800

 32,600

 36,000

 114,200

 100

 300

 400

 500

 500

 1,400

 2,000

 2,000

 3,700

 4,100

 4,600

 5,100

 5,300

 7,000

 7,400

 7,800

 12,700

 13,000

 13,500

 29,100

 29,600

 33,100

 100,000

16,292

 60,480

 17,626

 

 10,710

 17,730

 10,512

 15,380

 58,450

 

 105,000

 28.0000

 30.0000

 31.0000

 29.0000

 33.0000

 30.0000

 31.0000

 31.0000

 40.0000

 37.0000

 28.0000

 35.0000

 31.0000

 31.0000

 36.0000

 31.0000

 30.0000

 29.0000

 37.0000

 30.0000

 33.0000

 36.0000

 28.0000

 25.0000

 34.0000

 29.0000

 34.0000

 33.0000

 30.0000

 27.0000

 35.0000

 34.0000

 30.0000

 31.0000

 32.0000

 36.1000

 32.0000

 33.6500

 30.0000

 32.0000

 30.0000

 36.0000

 32.0000

 27.0000

 37.0000

 32.0000

 33.0000

 29.0000

 33.0000

 33.0000

 35.0000

 31.0000

 35.0000

 30.0000

 32.0000

 32.0000

 29.0000

 35.0000

 32.0000

 35.0000

 29.0000

 29.5000

 26.0000

 26.0000

 29.5000

 30.0000

 22.0000

 24.0000

 25.0000

 35.0000

 23.0000

 28.0000

 25.0000

 27.0000

 27.0000

 31.0000

 25.0000

 32.0000

 30.0000

 30.0000

 27.0000

 29.0000

 28.0000

 30.0000

 28.0000

 29.0000

 25.0000

 35.0000

 30.0000

 33.0000

 35.0000

 28.0000

 20.0000

 34.0000

 33.0000

 28.0000

 31.0000

 30.0000

 32.0000

 29.0000

 32.0000

 33.0000

 29.0000

 30.0000

 27.0000

 28.5000

 31.0000

 32.0000

 31.0000

 32.0000

 32.0000

 27.0000

30.6900

 N/A

 N/A

 

 N/A

 N/A

 N/A

 N/A

 N/A

 

 N/A

 

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

European

American

European

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

N/A

N/A

 

N/A

N/A

N/A

N/A

N/A

 

N/A

 

19/12/14

18/07/14

30/05/14

18/07/14

19/12/14

19/12/14

15/08/14

19/12/14

16/01/15

19/09/14

19/09/14

19/12/14

23/05/14

18/07/14

19/12/14

19/09/14

19/09/14

19/12/14

19/12/14

23/05/14

15/08/14

19/09/14

20/06/14

16/01/15

16/05/14

16/05/14

20/06/14

20/06/14

16/05/14

16/01/15

19/09/14

19/09/14

20/06/14

20/06/14

16/05/14

10/06/14

20/06/14

22/07/14

16/01/15

16/05/14

30/05/14

16/05/14

15/08/14

19/09/14

20/06/14

18/07/14

19/09/14

19/09/14

16/05/14

18/07/14

20/06/14

16/05/14

16/05/14

06/06/14

19/12/14

19/09/14

20/06/14

16/01/15

16/01/15

19/09/14

23/05/14

30/05/14

20/06/14

19/09/14

23/05/14

19/12/14

16/01/15

19/12/14

19/12/14

16/05/14

20/06/14

19/09/14

19/09/14

19/09/14

16/01/15

20/06/14

20/06/14

20/06/14

19/09/14

30/05/14

16/05/14

16/05/14

18/07/14

20/06/14

20/06/14

19/09/14

16/01/15

16/01/15

16/05/14

19/09/14

19/12/14

15/08/14

16/01/15

18/07/14

20/06/14

16/05/14

15/08/14

16/01/15

19/09/14

20/06/14

18/07/14

16/05/14

18/07/14

18/07/14

20/06/14

30/05/14

18/07/14

16/05/14

16/05/14

19/12/14

16/01/15

16/01/15

06/10/14

23/04/15

27/05/14

 

08/09/14

08/09/14

08/09/14

21/04/15

02/09/14

 

02/09/14

 

3.         AGREEMENTS TO PURCHASE OR SELL ETC.

 

Full details should be given so that the nature of the interest or position can be fully understood:

 

 

 

 

 

 

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 



[1] Includes shares of Pfizer common stock held by the directors and, to their knowledge after inquiry, their close relatives (whether directly or in trust).

[2] Includes 9,614 shares held in the Pfizer Savings Plan ("PSP"), which is a U.S. tax qualified 401(k) plan.  PSP participants receive company matching contributions in, and can also defer participant contributions into, a fund comprised of Pfizer stock which is unitized.

[3] For further information regarding the directors' stock awards and options, see Pfizer's Proxy Statement for its 2014 Annual Meeting of Shareholders, which was filed with the U.S. Securities and Exchange Commission on March 13, 2014 and which is not incorporated into, and does not form part of, this announcement.

[4] When vested, Restricted Stock Units ("RSUs") entitle the holder to receive a specified number of shares of Pfizer common stock, including shares resulting from dividend equivalents paid on such RSUs. In virtually all instances, the RSUs vest after three years of continuous service from the grant date.

[5] Performance Share Awards ("PSAs") vest after three years of continuous service from the grant date. The number of shares paid, including shares resulting from dividend equivalents, depends upon the achievement of predetermined goals related to Pfizer's total share return as compared to an industry peer group, for the three-year performance period from the year of the grant date.

[6] "Deferred" means that the RSU or PSA has vested, but was deferred. Deferred PSAs and RSUs may only be deferred into the Pfizer stock unit fund under the Pfizer Inc. Deferred Compensation Plan. The Pfizer stock unit fund is credited with dividend equivalent units which are reinvested.

[7] The Nonfunded Deferred Compensation and Supplemental Savings Plan extends the PSP, on a non-qualified basis, for deferral of compensation in excess of the tax code limitations under the same terms.

[8] Total Shareholder Return Units ("TSRUs") entitle the holders to receive a number of shares of Pfizer common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividends accumulated during the five-year or seven-year term, if and to the extent the total value is positive. The settlement price is the average closing price of Pfizer common stock during the 20 trading days ending on the fifth or seventh anniversary of the grant as applicable; the grant price is the closing price of Pfizer common stock on the date of the grant. The TSRUs are automatically settled on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant, after which time there is no longer a risk of forfeiture.

[9] Stock options, when vested, entitle the holder to purchase a specified number of shares of Pfizer common stock at a price per share equal to the closing market price of Pfizer common stock on the date of grant.

[10] Director units (each equivalent to a share of Pfizer common stock) are awarded under Pfizer's Director compensation program.  Units are not payable until the Director ceases to be a member of the Board, at or after which time they are paid in cash or in shares of Pfizer stock at the Director's election.

[11] Includes 16,335 units resulting from the conversion into Pfizer units of previously deferred Warner-Lambert director compensation under the Warner-Lambert 1996 Stock Plan.

[12] The information in this section was provided to Pfizer by the relevant adviser

[13] Pfizer has entered into contracts with various financial institutions in connection with its ongoing share repurchase program whereby those financial institutions agree to purchase shares of Pfizer common stock (up to a certain aggregate dollar amount) during a specified time period.

[14] The information in this section was provided to Pfizer by J.P. Morgan Securities LLC.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEEBFLFLZEFZBBQ

a d v e r t i s e m e n t